DK1719507T3 - Beta-2 adrenoceptoragonister til behandling af bindevævsygdomme i huden - Google Patents

Beta-2 adrenoceptoragonister til behandling af bindevævsygdomme i huden

Info

Publication number
DK1719507T3
DK1719507T3 DK06007632.0T DK06007632T DK1719507T3 DK 1719507 T3 DK1719507 T3 DK 1719507T3 DK 06007632 T DK06007632 T DK 06007632T DK 1719507 T3 DK1719507 T3 DK 1719507T3
Authority
DK
Denmark
Prior art keywords
beta
skin
treatment
connective tissue
tissue disorders
Prior art date
Application number
DK06007632.0T
Other languages
Danish (da)
English (en)
Inventor
Morten Sloth Weidner
Original Assignee
Astion Dev As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Dev As filed Critical Astion Dev As
Application granted granted Critical
Publication of DK1719507T3 publication Critical patent/DK1719507T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK06007632.0T 2005-04-13 2006-04-12 Beta-2 adrenoceptoragonister til behandling af bindevævsygdomme i huden DK1719507T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200500529 2005-04-13

Publications (1)

Publication Number Publication Date
DK1719507T3 true DK1719507T3 (da) 2010-11-01

Family

ID=36703472

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06007632.0T DK1719507T3 (da) 2005-04-13 2006-04-12 Beta-2 adrenoceptoragonister til behandling af bindevævsygdomme i huden

Country Status (28)

Country Link
US (4) US8426475B2 (enExample)
EP (1) EP1719507B1 (enExample)
JP (1) JP5021621B2 (enExample)
KR (1) KR101355422B1 (enExample)
CN (1) CN101203214B (enExample)
AR (1) AR054249A1 (enExample)
AT (1) ATE473735T1 (enExample)
AU (1) AU2006233502B2 (enExample)
BR (1) BRPI0609361A2 (enExample)
CA (1) CA2604758C (enExample)
CY (1) CY1111541T1 (enExample)
DE (1) DE602006015387D1 (enExample)
DK (1) DK1719507T3 (enExample)
EA (1) EA016082B1 (enExample)
ES (1) ES2348920T3 (enExample)
HR (1) HRP20100552T1 (enExample)
IL (1) IL186491A (enExample)
MX (1) MX2007012794A (enExample)
MY (1) MY147864A (enExample)
NO (1) NO331211B1 (enExample)
NZ (1) NZ562940A (enExample)
PL (1) PL1719507T3 (enExample)
PT (1) PT1719507E (enExample)
RS (1) RS51464B (enExample)
SI (1) SI1719507T1 (enExample)
TW (1) TWI366457B (enExample)
WO (1) WO2006108424A2 (enExample)
ZA (1) ZA200708748B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0604826D0 (en) * 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders and pain
CA2656312C (en) 2006-07-10 2014-09-09 Intervet International B.V. Zilpaterol enantiomer compositions and methods of making and using such compositions
GB0624757D0 (en) * 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
GB0805535D0 (en) * 2008-03-27 2008-04-30 Univ Leicester Scar prevention
US20120252831A1 (en) * 2011-03-31 2012-10-04 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating scleroderma therewith
CN102267917B (zh) * 2011-06-15 2013-07-31 浙江工业大学 一种盐酸甲氧那明的合成方法
EP2849577A1 (en) * 2012-05-18 2015-03-25 Intervet International B.V. A method of enhancing performance in broiler chickens
GB2513297A (en) 2013-03-08 2014-10-29 Univ Leicester Methods
CN104606177B (zh) * 2014-11-21 2018-02-02 苏州君宁新药开发中心有限公司 左旋(r)沙丁胺醇制剂在治疗皮肤及粘膜创伤溃疡的药物应用
WO2018000098A1 (en) * 2016-06-30 2018-01-04 Cipher Pharmaceuticals Inc. Treatment of inflammatory myopathies
CN106580978A (zh) * 2016-11-30 2017-04-26 郑州仁宏医药科技有限公司 一种治疗皮炎的西药组合物及其应用
US10576043B2 (en) * 2017-08-10 2020-03-03 Avro Life Sciences, Inc. Transdermal drug delivery system
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
BR112021018481A2 (pt) * 2019-03-27 2021-11-23 Curasen Therapeutics Inc Agonista adrenérgico beta e métodos para usar o mesmo
CA3161376A1 (en) 2019-12-18 2021-06-24 Anthony P. FORD Methods for improving neurological diseases and disorders
CN112300237A (zh) * 2020-04-13 2021-02-02 苏州恩泰新材料科技有限公司 海豹胆酸的制备方法及其应用
KR20230084242A (ko) * 2020-10-09 2023-06-12 엠씨2 테라퓨틱스 리미티드 피부과적 병태의 치료
CN116236467B (zh) * 2023-02-07 2023-10-27 中国人民解放军总医院 西马特罗或其衍生物的新用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA7468B (en) 1973-01-16 1974-11-27 J Voorhees Compositions and treatment of proliferatave skin diseases with phosphodiesterase inhibitors
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
SU895445A1 (ru) * 1980-05-15 1982-01-07 Военно-Медицинская Краснознаменная Академия Им. С.М.Кирова Способ лечени кожных форм красной волчанки
US4574129A (en) 1984-01-31 1986-03-04 Bristol-Myers Company Topical nonsteroidal anti-inflammatory methods
JPS61154201A (ja) 1984-12-26 1986-07-12 Matsushita Electric Ind Co Ltd 誘電体フイルタ
US4699777A (en) 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea
PH25150A (en) 1986-06-05 1991-03-13 Ciba Geigy Ag Novel pharmaceutical preparation for topical application
US4980159A (en) 1989-05-23 1990-12-25 Bristol-Myers Squibb Company Processes and compositions for the topical application of β-adrenergic agonists for pilomotor effects
RU2092105C1 (ru) * 1989-11-20 1997-10-10 Нижегородский научно-исследовательский кожно-венерологический институт Способ определения терапевтической тактики у больных очаговой склеродермией и дискоидной красной волчанкой
DE4014252A1 (de) * 1990-05-04 1991-11-07 Boehringer Ingelheim Vetmed Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
JP2611073B2 (ja) 1990-07-26 1997-05-21 モンサント カンパニー 新規ポリアミンの製造方法
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
GB9107196D0 (en) * 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
JP3294876B2 (ja) 1992-07-20 2002-06-24 トキコ株式会社 給油装置
WO1995019336A1 (de) 1994-01-12 1995-07-20 Iovis Biomedical And Pharmaceutical Consultants Phenylethanolaminether und ihre verwendung als beta-adrenorezeptor-agonisten
JPH07304647A (ja) 1994-05-09 1995-11-21 Kao Corp マッサージ用組成物
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
GB9510162D0 (en) * 1995-05-19 1995-07-12 Bouras Elias Compositions for the treatment of skin conditions
JPH09110674A (ja) 1995-10-16 1997-04-28 Kao Corp 浴用剤組成物
FR2740040B1 (fr) 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
AU737608B2 (en) * 1997-04-30 2001-08-23 Courage Corporation Pty Ltd Composition and methods using an eutomer
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
AU8533101A (en) * 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
CA2428753C (en) 2000-11-17 2013-05-21 Universita Degli Studi Di Cagliari Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
TWI334778B (en) 2001-12-03 2010-12-21 Wyeth Corp Inhibitors of cytosolic phospholipase a2
SI1496917T1 (sl) 2002-04-19 2006-06-30 Astion Dev As Kombinacija beta-2-adrenoceptorskih agonistov in aminosladkorjev in njihova uporaba za zdravljenje imonomodulatornih motenj
AU2003228133A1 (en) 2002-04-22 2003-11-03 Umc Utrecht Holding B.V. Reduction of unwanted immune reactions
WO2003092617A2 (en) * 2002-05-03 2003-11-13 Combinatorx, Incorporated Combinations for the treatment of inflammatory skin disorders
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US20040229849A1 (en) 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040220153A1 (en) 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
HRP20050355A2 (en) * 2002-09-24 2005-10-31 Combinatorx Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
NZ541234A (en) * 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
WO2004073614A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
WO2004091540A2 (en) * 2003-04-15 2004-10-28 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
WO2005004852A1 (en) 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
TW200522932A (en) 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
DE602004031356D1 (de) * 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
WO2005089741A2 (en) * 2004-03-17 2005-09-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
WO2005102296A2 (en) 2004-04-23 2005-11-03 Heptagen Limited Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
MX2007002742A (es) * 2004-09-07 2007-05-23 Sosei R & D Ltd Tratamiento de padecimientos inflamatorios y dolor.

Also Published As

Publication number Publication date
US20170157068A1 (en) 2017-06-08
PL1719507T3 (pl) 2010-12-31
IL186491A0 (en) 2008-08-07
MY147864A (en) 2013-01-31
KR101355422B1 (ko) 2014-02-06
ZA200708748B (en) 2010-03-31
TW200719882A (en) 2007-06-01
WO2006108424A2 (en) 2006-10-19
CA2604758A1 (en) 2006-10-19
CN101203214B (zh) 2012-11-21
JP5021621B2 (ja) 2012-09-12
CN101203214A (zh) 2008-06-18
CA2604758C (en) 2014-11-25
SI1719507T1 (sl) 2010-11-30
AU2006233502A1 (en) 2006-10-19
JP2008535873A (ja) 2008-09-04
NZ562940A (en) 2010-02-26
HK1091739A1 (en) 2007-01-26
PT1719507E (pt) 2010-10-21
EA200702204A1 (ru) 2008-04-28
HRP20100552T1 (hr) 2010-11-30
EP1719507A1 (en) 2006-11-08
RS51464B (sr) 2011-04-30
ATE473735T1 (de) 2010-07-15
KR20080005957A (ko) 2008-01-15
TWI366457B (en) 2012-06-21
AU2006233502B2 (en) 2011-07-28
CY1111541T1 (el) 2015-08-05
US20060235048A1 (en) 2006-10-19
WO2006108424A9 (en) 2007-08-09
US8426475B2 (en) 2013-04-23
EP1719507B1 (en) 2010-07-14
US20130237607A1 (en) 2013-09-12
AR054249A1 (es) 2007-06-13
US9907765B2 (en) 2018-03-06
IL186491A (en) 2011-12-29
MX2007012794A (es) 2008-02-22
NO20075527L (no) 2008-01-14
NO331211B1 (no) 2011-10-31
US20190125699A1 (en) 2019-05-02
BRPI0609361A2 (pt) 2010-03-30
DE602006015387D1 (de) 2010-08-26
WO2006108424A3 (en) 2006-12-14
EA016082B1 (ru) 2012-02-28
ES2348920T3 (es) 2010-12-17

Similar Documents

Publication Publication Date Title
NO20075527L (no) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
DK1948177T3 (da) Anvendelse af flibanserin til behandling af præmenopausale seksuelle lystforstyrrelser
DK2409728T3 (da) System til ultralydsbehandling af væv
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
PT2444424T (pt) Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
DK1890684T3 (da) Behandling af søvn/vågenhedsforstyrrelser
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
DK1863899T3 (da) Hudbehandlingspræparater
BRPI0715728A8 (pt) tratamento de distúrbios cartilaginosos
EA201170672A1 (ru) Соединения, пригодные для лечения целлюлита
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
DK1838318T3 (da) Anvendelse af oxycodon til behandling af visceral smerte
BRPI0506723A (pt) métodos para o tratamento de distúrbios vasculares
ITRM20050446A1 (it) Uso di stilbeni idrossilati e glucosidati per la prevenzione ed il trattamento di patologie oculari.
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602006013945D1 (de) Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck